Disseminated Effects in Agent Based Models: A Potential Outcomes Framework and Application to Inform Pre-Exposure Prophylaxis Coverage Levels for HIV Prevention by Buchanan, Ashley L et al.
University of Rhode Island 
DigitalCommons@URI 
Pharmacy Practice Faculty Publications Pharmacy Practice 
2020 
Disseminated Effects in Agent Based Models: A Potential 
Outcomes Framework and Application to Inform Pre-Exposure 
Prophylaxis Coverage Levels for HIV Prevention 
Ashley L. Buchanan 
S. Bessey 
William C. Goedel 
Maximilian King 
Eleanor J. Murray 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.uri.edu/php_facpubs 
The University of Rhode Island Faculty have made this article openly available. 
Please let us know how Open Access to this research benefits you. 
This is a pre-publication author manuscript of the final, published article. 
Terms of Use 
This article is made available under the terms and conditions applicable towards Open Access 
Policy Articles, as set forth in our Terms of Use. 
Authors 
Ashley L. Buchanan, S. Bessey, William C. Goedel, Maximilian King, Eleanor J. Murray, Samuel Friedman, 
M. Elizabeth Halloran, and Brandon D.L. Marshall 
Disseminated Effects in Agent Based Models: A Potential Outcomes Framework and 
Application to Inform Pre-Exposure Prophylaxis Coverage Levels for HIV Prevention  
 
Ashley L Buchanan, S. Bessey, William C Goedel, Maximillian King, Eleanor J Murray, Samuel 
Friedman, M. Elizabeth Halloran, and Brandon DL Marshall 
 
Correspondence to Dr. Ashley Buchanan, Department of Pharmacy Practice, College of 
Pharmacy, University of Rhode Island, 7 Greenhouse Road, Kingston, RI 02881 (email: 
Buchanan@uri.edu; phone: 401-874-4739; fax: 401-874-2717) 
 
Author affiliations: Department of Pharmacy Practice, College of Pharmacy, University of 
Rhode Island, Kingston, RI (Ashley Buchanan); Department of Epidemiology, Brown School 
of Public Health, Providence, RI (S. Bessey, William Goedel, Maximillian King, Brandon 
Marshall); Department of Epidemiology, Boston University School of Public Health, Boston, 
MA (Eleanor Murray); Department of Population Health, School of Medicine, New York 
University, New York, NY (Samuel Friedman); Vaccine and Infectious Disease Division, Fred 
Hutchinson Cancer Research Center, and Department of Biostatistics, University of 
Washington, Seattle, WA (M. Elizabeth Halloran) 
 
Acknowledgements: AB, MK, BM, SF, and MEH were supported by the NIH Avenir grant 
1DP2DA046856-01. SF was also supported by NIH grants DP1DA034989 and 
P30DA011041. WCG was also supported by NIH grants R25MH083620 and F31MH121112. 
EJM was supported by NIH grant R21HD098733. The content is solely the responsibility of 
the authors and does not necessarily represent the official views of the National Institutes 
of Health. 
 
Conflicts of interest:  None declared 
 
Running Head: Agent-based Models with Disseminated Effects 
 
 2 
Keywords: HIV Prevention; Men who have sex with men; Pre-exposure prophylaxis; Agent 
based models; Interference/dissemination 
Abbreviations: Pre-exposure prophylaxis (PrEP); Tenofovir disoproxil fumarate (TDF) 
emtricitabine (FTC); Men who have sex with men (MSM); Agent-based model (ABM) 
 
Word Count: 4,000/4000 (Abstract: 199/200) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 3 
ABSTRACT 
 
Pre-exposure prophylaxis (PrEP) for HIV prevention may not only benefit the individual 
who uses it, but also their uninfected sexual risk contacts. We developed an agent-based 
model using a novel trial emulation approach to quantify disseminated effects of PrEP use 
among men who have sex with men in Atlanta, GA. Components (subsets of agents 
connected through partnerships in a sexual network, but not sharing sexual partnerships 
any other agents) were first randomized to an intervention coverage level or control, then 
within intervention components, eligible agents were randomized to PrEP. We estimated 
direct and disseminated (indirect) effects using randomization-based estimators and 
reported corresponding 95% simulation intervals (SI) across scenarios ranging from 10% 
to 90% coverage in the intervention components. A population of 11,245 agents was 
simulated for two years, with an average of 1,551 components identified. Comparing agents 
randomized to PrEP in 70% coverage components to control agents, there was an 15% 
disseminated risk reduction in HIV incidence (95% SI = 0.65, 1.05). Individuals not on PrEP 
may receive a protective benefit by being in a sexual network with higher PrEP coverage. 
Agent-based models are useful to evaluate possible direct and disseminated effects of HIV 
prevention modalities in sexual networks.   
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INTRODUCTION 
 
Once daily pre-exposure prophylaxis (PrEP) is a single tablet containing tenofovir 
disoproxil fumarate (TDF) and emtricitabine (FTC) that is effective for preventing HIV 
transmission among men who have sex with men (MSM) (1, 2). Despite strong evidence of 
its effectiveness (3, 4), access to PrEP among MSM remains low, particularly among MSM in 
the Southern United States who experience among the highest incidence and prevalence 
burdens of HIV infection among all groups in the United States (5-7).  
Traditional randomized clinical trials assessing the effect of PrEP use on HIV 
incidence only consider the direct (individual) effect of reducing HIV incidence among 
individuals who use PrEP.  However, PrEP for HIV prevention may not only benefit the 
individual user, but also their sexual risk contacts (8). In preventing HIV acquisition among 
an individual who uses PrEP, the possibility of secondary transmission to this individual’s 
other HIV-uninfected sexual risk contacts and possibly their partners’ partners is also 
eliminated (9). This feature (common to other prophylactic therapies such as vaccines) is 
referred to as spillover, dissemination, or interference (10, 11). Estimators of the maximal 
attainable benefit of an intervention like PrEP, referred to as its composite (total) effect, 
should account for both the impact of the intervention on its users, as well as the impact of 
the intervention on individuals who did not use the intervention themselves, but were 
connected to users.  
 In causal inference methodology, a fundamental assumption of much work is the 
stable unit treatment value assumption (SUTVA) (12), which includes an assumption of no 
dissemination, or interference, between individuals. An assumption of no dissemination 
requires that the potential outcomes of one individual be unaffected by the treatment or 
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intervention assignment of other individuals. Both effects are readily identifiable in two-
stage randomized trials (Figure 1) (10, 13), where randomization first occurs at a group 
level (i.e., groups of connected individuals are randomly assigned to an intervention 
allocation strategy or control) and then at an individual level (i.e., individuals are assigned 
to receive an intervention or not according to their group allocation strategy) (Figure 2). 
The disseminated (indirect) effect of the intervention is defined as the effect of being in an 
intervention group and randomized to not receive an intervention versus being in a control 
group.  
We adapted a previously published agent-based model (ABM) (14, 15), simulating 
HIV transmission in a hypothetical population of MSM in Atlanta, GA, USA (16, 17), to 
emulate a two-stage randomized clinical trial (18), which may be considered unfeasible or 
currently unethical to implement in this population, as PrEP is currently FDA-approved for 
HIV prevention and often used as an active control in studies of ‘next generation’ HIV 
prevention modalities (19). We selected the city of Atlanta, GA as a case study because of 
the high HIV incidence and prevalence among MSM in this setting (20). Access to PrEP 
could be improved in this population and benchmarks for coverage could be used to inform 
and expedite efforts to end the HIV epidemic in the Southeastern United States (21). We 
aim to evaluate the magnitude and direction of possible disseminated effects of PrEP use 
among MSM in Atlanta, GA. 
METHODS 
Model Setting 
We adapted a previously published model of PrEP uptake and HIV transmission 
among MSM in Atlanta and complete details about this model can be found in (14). We 
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employed a discrete-time, stochastic, agent-based model to simulate a two-stage 
randomized trial of PrEP for HIV prevention in a population of MSM (aged 18-65 years) in 
Atlanta, GA, USA and followed agents for two years from 2015 to 2017 (14, 22). Each agent 
in the model was assigned characteristics related to demographic, behavioral, HIV status, 
and clinical status. The simulated agent population was 51% African American. Aligning 
with empirical estimates (20, 23, 24), we assumed that, among African American agents, 
the median age was 32 years, 30% were using substances, 32% had a preferred receptive 
sexual role, and 24% had a preferred insertive sexual role. Among white non-Hispanic 
agents, we assumed that the median age was 35 years, 49% were using substances, 23% 
had a preferred receptive sexual role, and 23% had a preferred insertive sexual role. 
Whenever possible, each individual agent’s behaviors and characteristics were 
parameterized based on empirical estimates from the study setting. Several parameter 
values (e.g., those governing initial HIV prevalence and treatment) were stratified by race 
(14), reflecting the substantial racial/ethnic disparities in HIV incidence and prevalence in 
this setting (20).   
The model simulated a dynamic population with 1,000 total simulations per 
scenario, where the scenarios corresponded to a series of two-stage randomized trials. 
Because this ABM was simulating a randomized trial with a short duration of follow-up, 
agents and their characteristics were generated in a base population and no new agents 
were allowed to enter the population. Python (version 2.7.12) was used for coding, testing 
and performing sensitivity analyses of this model and R (Version 3.5.1) was used to analyze 
the model output. Additional information regarding parameter values, key model 
assumptions, and data sources are included in the Supplemental Appendix. 
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Sexual Networking and Components 
Prior to “enrollment” (i.e., model initialization) in the hypothetical trial, agents 
formed sexual partnerships to create a sexual network of many distinct components. A 
sexual network component was defined as a subset of the agents in a network that are all 
connected through at least one partnership and not connected to any other agents in the 
network. After two-stage randomization, where components were first randomized to an 
intervention allocation strategy, then within each component, agents were randomized 
according to that strategy, annual number of partners and number of sex acts were 
assumed to follow stochastic distributions with parameters based on the literature (20, 
25). At discrete time-steps (measured in months since randomization) over the two years 
of follow-up, relationships were not dissolved and new relationships were not formed, but 
rather sexual networks were assumed to be static, as ascertained prior to enrollment in the 
trial. This is akin to a randomized trial design, where often the sexual networks are 
ascertained only once at the start of the study (26, 27). These partnerships at enrollment 
were used to determine network components of size 2 to 100 agents.  
HIV Transmission, Treatment and Progression 
Detailed HIV transmission, treatment, and disease progression processes and 
parameters have been described in detail previously (14, 15). At each monthly interval, 
agents had a certain number of sex acts with their partners. The probability of condom use 
was lower if the agent used substances and also decreased as a function of the number of 
prior contacts with a given partner. In the absence of any biomedical intervention (PrEP or 
treatment as prevention, known as TasP), any condomless sex act in a serodiscordant 
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partnership had a non-zero probability of HIV transmission (per-act probability for 
condomless receptive anal intercourse was 1.38% and insertive was 0.11%) (28). This 
probability varied depending upon the following factors: if the HIV-negative agent was 
randomized to PrEP; among HIV-negative agents randomized to PrEP, their adherence to 
PrEP; and among HIV-infected agents, knowledge of their HIV status, HIV treatment, and if 
they achieved viral suppression after initiation of HIV treatment.  
Impact of Substance Use on Agent Behavior 
We included an agent class characterized by substance use, which was defined at 
model initialization and remained stable for the duration of the study.  The prevalence of 
substance use, defined as any drug use, was set to 30% among African Americans and 
48.5% among whites (20, 23). In the model, substance use influenced PrEP adherence, 
condomless sex, and assortative mixing in sexual partner selection. Agents who were 
defined as substance users had a 35% lower probability of achieving optimal adherence to 
PrEP (8), and a 20% higher probability of engaging in condomless sex (29). In addition, we 
assumed that 20% of substance using agents mix with other substance using agents.  
Oral Pre-Exposure Prophylaxis (PrEP) Use and HIV Treatment 
After enrollment in the hypothetical trial, eligible agents who were randomized to the PrEP 
intervention were assumed to continue to receive PrEP for the two-year duration of the 
trial. For the two-year duration of this simulated trial, all agents were retained in the study 
and no agents died. At enrollment in the trial, agents were classified as optimally adherent 
to PrEP (defined as 4 or more doses per week), or were sub-optimally adherent (defined as 
2 to 4 doses per week). Those with optimal adherence had a 96% reduction in the per-act 
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probability of HIV acquisition, while those with partial adherence had only a 76% 
reduction (30). Agents on ART were less likely to progress to AIDS than other HIV-infected 
agents. This was achieved through a scalar reduction in profession probability, with the 
reduction dependent on ART adherence (31, 32). 
Simulated Trial Design 
The current study simulated a two-stage randomized trial (Figure 2). In the first stage, 
network components were randomized 1:1 to either receive a certain PrEP coverage 
(referred to as “intervention components) or no PrEP coverage (referred to as “control 
components) (18, 33). PrEP coverage level was defined as the proportion of eligible agents 
receiving PrEP in a component, where eligible agents were defined as those who were HIV-
negative with one or more partnerships and ages 18 to 65 years old at enrollment. PrEP 
coverage was assigned at baseline. We assumed that agents assigned to PrEP take at 
minimum two or more doses per week with adherence pattern remained stable for the 
duration of follow-up. We assumed that PrEP adherence did not change PrEP coverage 
following an intention-to-treat approach and that PrEP coverage generally remained stable 
during follow-up. HIV-negative agents in each intervention component were randomized to 
PrEP according to the assigned coverage level. We consider the following scenarios: PrEP 
coverage level (in each component) of 10% to 90%, in increments of 10%.  
At the baseline visit of the trial, agents who were randomized to PrEP initiated their 
intervention and all agents, regardless of HIV status, were followed for two years to 
ascertain their HIV status. We assumed no drop out (i.e., 100% retention on PrEP over the 
two years of follow-up). We also assumed over the two years that the probability of death 
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is zero, which may be reasonable given the age range of agents and short duration of 
follow-up. 
Causal Inference Methods for Evaluation of Dissemination using ABMs 
Several assumptions are needed to identify causal effects in the presence of 
dissemination. We assumed partial interference (13); that is, the intervention assignment 
affects the outcomes of other agents in the same component only, but does not extend to 
other agents outside their component. We also assumed stratified interference, in which an 
agent’s potential outcome is dependent only on their own intervention assignment and the 
proportion of those randomized to the intervention in their component (34). We also make 
the usual assumptions required for causal inference (exchangeability, consistency, and 
positivity) (35). Due to randomization at both the component- and agent-level, marginal 
exchangeability holds: Components randomized to the intervention will be, on average, 
comparable to components randomized to the control.  Furthermore, within each 
component, agents randomized to the intervention will be, on average, comparable to 
agents randomized to the control. Positivity means that there is a non-zero probability of 
exposure within each level of the covariates (36, 37). We assumed an independent 
Bernoulli allocation strategy for intervention assignment within each intervention 
component (13). 
 In our simulated trial, the sexual risk component sizes vary, so we employed estimators 
that account for varying component size (38). Assume there are 𝐼 components and each of 
the component has 𝑛𝑖 individuals indexed by 𝑗 = 1,2, . . . , 𝑛𝑖 and ∑ 𝑛𝑖 = 𝑁.
𝐼
𝑖=1  Let 𝑌𝑖𝑗 , 
𝐴𝑖𝑗 represent an observed outcome and intervention assignment status of 𝑗
𝑡ℎ agent in 
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component 𝑖. In addition, 𝐶𝑖 denotes the intervention assignment strategy at the 
component level that corresponds to intervention coverage denoted by 𝛼, where 𝐶𝑖 = 1 if 
the intervention allocation strategy was 𝛼 and 𝐶𝑖 = 0, otherwise.  Let 𝐴(𝑛) be the set of 
vectors of all possible exposure allocations of length 𝑛. We consider the potential outcome 
for agent 𝑗 in component 𝑖 as 𝑌𝑖𝑗(𝐶𝑖 = 𝑐, 𝐴𝑖𝑗 = 𝑎). Because we have a “pure control group”, 
there are three possible combinations of the following potential outcomes: 
𝑌𝑖𝑗(1,1), 𝑌𝑖𝑗(1,0), 𝑌𝑖𝑗(0,0). By (causal) consistency (39-41), the observed outcome is a 
function of the intervention assignment and potential outcomes; that is, 𝑌𝑖𝑗
𝑜𝑏𝑠 =
𝐶𝑖𝐴𝑖𝑗𝑌𝑖𝑗(1,1) + 𝐶𝑖(1 − 𝐴𝑖𝑗)𝑌𝑖𝑗(1,0) + (1 − 𝐶𝑖)𝑌𝑖𝑗(0,0). Let 𝑇𝑐𝑎 = {(𝑖, 𝑗): 𝐶𝑖 = 𝑐 𝑎𝑛𝑑 𝐴𝑖𝑗 =
𝑎} to denote the set of components and agents who are assigned to 𝐶𝑖 = 𝑐 and 𝐴𝑖𝑗 = 𝑎.  
 In the setting with varying component sizes, there are two types of estimands: 
component-weighted estimands that assign equal weight to components, regardless of the 
number of individuals in each component; and agent-weighted estimands that assign equal 
weight to agents, regardless of the distribution across components. The direct (i.e., 
individual) effect measures the additional benefit of being on PrEP beyond being in an 
intervention component with a fixed PrEP coverage level (Figure 1) and is defined as  
𝐷𝐸 = ∑ 𝑤𝑖
∗𝐼
𝑖=1 ∑ [𝑌𝑖𝑗(1,1) − 𝑌𝑖𝑗(1,0)]
𝑛𝑖
𝑗=1  ; 
The disseminated (i.e., indirect) effect compares those who were not on PrEP themselves 
and in an intervention component, to those who were in a control component and is 
defined as 
𝐼𝐸 = ∑ 𝑤𝑖
∗𝐼
𝑖=1 ∑ [𝑌𝑖𝑗(1,0) − 𝑌𝑖𝑗(0,0)]
𝑛𝑖
𝑗=1  ; 
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The composite (i.e., total) effect is the combined direct and disseminated effect and is 
defined as 
𝑇𝐸 = ∑ 𝑤𝑖
∗𝐼
𝑖=1 ∑ [𝑌𝑖𝑗(1,1) − 𝑌𝑖𝑗(0,0)]
𝑛𝑖
𝑗=1  ; 
The overall effect marginalizes over the agent exposure and compares intervention to 
control components; that is,  
𝑂𝐸 = ∑ 𝑤𝑖
∗𝐼
𝑖=1 ∑ [𝑌𝑖𝑗(1,⋅) − 𝑌𝑖𝑗(0,⋅)]
𝑛𝑖
𝑗=1 , 
where 𝑤𝑖
∗ =
1
𝐼𝑛𝑖
 corresponds to component-weighted estimands and 𝑤𝑖
∗ =
1
𝑁
 corresponds to 
agent-weighted estimands with 𝑁 = ∑𝑛𝑖.  
 To quantify these estimands, we employ the two-stage inverse probability weights 
𝑤𝑖
(0), 𝑤𝑖
(10), 𝑤𝑖
(11) as 𝑤𝑖
(11) =
1
𝑃𝑟(𝐶𝑖=1)
1
𝑃𝑟(𝐴𝑖𝑗=1|𝐶𝑖=1)
, 𝑤𝑖
(10) =
1
𝑃𝑟(𝐶𝑖=1)
1
𝑃𝑟(𝐴𝑖𝑗=0|𝐶𝑖=1)
, and 
𝑤𝑖
(0) =
1
𝑃𝑟(𝐶𝑖=0)
. Define 𝑤𝑖
(𝑐) =
1
𝑃𝑟(𝐶𝑖=𝑐)
. The weighted direct, disseminated, composite, and 
overall effect estimators are 
𝐷?̂? = ∑ 𝑤𝑖
∗𝑤𝑖
(11)𝑌𝑖𝑗
𝑜𝑏𝑠(1,1)(𝑖,𝑗)∈𝑇11 − ∑ 𝑤𝑖
∗𝑤𝑖
(10)𝑌𝑖𝑗
𝑜𝑏𝑠(1,0)(𝑖,𝑗)∈𝑇10 , 
 
𝐼?̂? = ∑ 𝑤𝑖
∗𝑤𝑖
(10)
𝑌𝑖𝑗
𝑜𝑏𝑠(1,0)(𝑖,𝑗)∈𝑇10 − ∑ 𝑤𝑖
∗𝑤𝑖
(0)
𝑌𝑖𝑗
𝑜𝑏𝑠(0,0)(𝑖,𝑗)∈𝑇00 , 
 
𝑇?̂? = ∑ 𝑤𝑖
∗𝑤𝑖
(11)𝑌𝑖𝑗
𝑜𝑏𝑠(1,1)(𝑖,𝑗)∈𝑇11 − ∑ 𝑤𝑖
∗𝑤𝑖
(0)𝑌𝑖𝑗
𝑜𝑏𝑠(0,0)(𝑖,𝑗)∈𝑇00 , 
 
𝑂?̂? = ∑ 𝑤𝑖
∗𝑤𝑖
(1)𝑌𝑖𝑗
𝑜𝑏𝑠(1,⋅)(𝑖,𝑗)∈𝑇1⋅ − ∑ 𝑤𝑖
∗𝑤𝑖
(0)𝑌𝑖𝑗
𝑜𝑏𝑠(0,⋅)(𝑖,𝑗)∈𝑇0⋅ . 
For example, the estimator of the disseminated effect is the weighted average of the 
outcomes among agents assigned to no PrEP in intervention components minus the 
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weighted average of the outcomes among agents in control components (Figure 1). These 
estimators are unbiased in a two-stage randomized design (12).  
Outcome Measures 
The primary outcome measure was cumulative HIV incidence over 24 months after 
randomization in the simulated trial. We examined the estimated HIV incidence for each 
component PrEP coverage level among the intervention group, separately for agents on 
PrEP and agents not on PrEP. These parameters were computed using nonparametric 
estimators, as described above, along with 95% simulation intervals (i.e., credible 
intervals) given the stochastic framework of these models (i.e., middle 95% of simulated 
output) (42). Comparisons were made between the intervention agents and control agents 
within each simulated trial and across trials comparing various intervention coverage 
levels. 
Sensitivity Analyses 
Because we are evaluating disseminated effects, the results may depend on not only the 
efficacy of PrEP, but also the number and probability of sexual partnerships, as well as the 
size of the components. We performed one-way sensitivity analyses to evaluate the impact 
of modifying adherence to PrEP and maximum PrEP efficacy to prevent HIV (see 
Supplemental Appendix).  Specifically, we assessed the following: probability of 
partnership, baseline number of sexual acts, adherence to PrEP, efficacy of PrEP for 
suboptimal adherence, and maximum component size. We also performed a sensitivity 
analysis excluding the substance use agent class. 
RESULTS 
 14 
There were 11,245 agents in the simulated population, followed from 2015 to 2017 with an 
average of 1,551 components identified in each iteration of the model. At enrollment in the 
entire simulated trial with 70% PrEP coverage, the HIV point prevalence was 29% (95% 
simulation interval (SI) = 27%, 30%).  The majority of components (48%) had low HIV 
prevalence (< 5%), while 26% had higher HIV prevalence (45% to 50%) at enrollment. 
Although our model considered a range of intervention coverage levels (Table 1), we 
focused the discussion of results on two simulated trial designs that provide insights into 
two strategies: (1) intervention components with lower (30%) PrEP coverage and (2) 
intervention components with higher (70%) PrEP coverage.   
We first report the average results from simulated trials with 30% coverage in the 
intervention components (Table 2). Within intervention components, there was an 
estimated 82% direct risk reduction in cumulative HIV incidence among agents on PrEP 
compared to agents not on PrEP (Risk Ratio (RR) = 0.18, 95% SI: 0.13, 0.24). Comparing 
agents not on PrEP within intervention components to agents within control components, 
the estimated disseminated effect was an estimated 8% risk reduction (RR = 0.92, 95% SI: 
0.79, 1.06). The estimated composite (combined direct and disseminated) effect was an 
estimated 83% risk reduction (RR = 0.17, 95% CI: 0.11, 0.22). Comparing agents within 
intervention components to those within control components, marginalizing over 
individual-level PrEP use, there was an estimated 30% reduction in the overall risk (RR = 
0.70, 95% SI: 0.60, 0.80).  
We then report the average results from simulated trials with 70% coverage in the 
intervention components (Table 2). The estimated direct effect was an 83% reduction (RR 
= 0.17, 95% SI = 0.13, 0.23) in cumulative HIV incidence among agents on PrEP compared 
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to agents not on PrEP within intervention components.  The estimated disseminated effect 
was a 15% reduction (RR = 0.85, 95% SI = 0.65, 1.05) in cumulative HIV incidence, which 
means that agents not on PrEP in the intervention group had lower cumulative HIV 
incidence, as compared to control agents. The estimated composite effect was an 85% 
reduction in the cumulative incidence of HIV, comparing agents on PrEP within 
intervention components to agents within control components (RR = 0.15, 95% SI = 0.11, 
0.20). Comparing agents within intervention components to those within control 
components, there was an estimated 65% reduction in the overall effect (RR = 0.35, 95% 
SI: 0.28, 0.42).  
Figure 3 displays the estimated direct and disseminated risk difference and risk 
ratio effects on cumulative incidence of HIV as a function of component PrEP coverage with 
95% simulation intervals. As the intervention coverage increases in a component, the 
estimated direct effect is attenuated towards the null, although this trend is more apparent 
on the difference scale. On the other hand, when the intervention coverage is increased in a 
component, the estimated disseminated effect increased in magnitude on both the 
difference and ratio scale.  
We performed one-way sensitivity analyses to assess the impact of our model 
parameterization on the results, specifically cumulative HIV incidence over two years. In 
Table S8 and S9 (see Supplemental Appendix), we display the HIV prevalence and 
cumulative incidence at the end of two years of follow-up after randomization based on a 
simulated trial with 30% and 70% coverage, respectively. The number of incident HIV 
infections among agents in the base case was typically between the estimates for the 
scenarios with the parameters either half or double the base case, except for annual sexual 
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partnerships. In a sensitivity analysis excluding the substance use agent class, the 
disseminated effect was stronger for 30% coverage trials (RD = -0.02 and RR = 0.65) and 
70% coverage trials (RD = -0.03 and RR = 0.24) (Table S4 to S7). The linear trends of the 
effects on the difference scale across increasing coverage levels were more visually 
apparent (Figure S2 to S3). We also displayed the estimated effects across the one-way 
sensitivity analysis (Tables S10 and S11, Figures S4 to S7). The estimated effects were 
typically attenuated towards the null on the difference scale and away from the null on the 
ratio scale. 
 
DISCUSSION 
We employed an ABM to simulate an idealized two-stage randomized trial to evaluate the 
direct and disseminated effects of PrEP among MSM in Atlanta (14). We observed 
disseminated effects of PrEP among those not randomized to PrEP, but who shared a sexual 
risk network component with agents randomized to PrEP (with up to a 15% reduction in 
cumulative HIV incidence at coverage level 70%). We found that increasing PrEP coverage 
levels in a component strengthens the disseminated effect on reducing HIV incidence 
among those who were not randomized to the intervention; however, increasing PrEP 
coverage also possibly weakens the direct effect among those who were randomized to the 
intervention on the difference scale only. In other words, the individual benefit of receiving 
PrEP depends on the coverage of PrEP in an individual’s network: the higher the 
proportion of one’s sexual partners is on PrEP, the smaller the absolute direct, additional 
individual benefit of therapy beyond being in an intervention component. This type of 
simulation study can help to inform PrEP coverage levels needed to reduce HIV incidence 
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below a targeted threshold, while considering the complex sexual risk networks in which 
MSMs are embedded, as well as considering related risk factors, such as substance use. 
Many evaluations of the efficacy and effectiveness of PrEP focus on overall effect 
without consideration of the sexual risk network in which these individuals are embedded 
(43). Many of these studies are individually-randomized designs and often lack inference 
regarding the influence of others in the sexual network component or study cluster. Overall 
effects depend on spurious features of the study design, including the size of the 
components and PrEP coverage in each component. Therefore, it will likely not be 
generalizable from one study to the next or to any scaled-up population, unless these 
features remain constant (44).  In this ABM, we observed many scenarios contrasting 
adjacent coverage levels for which the overall effect estimate was closer to the null, while 
the composite effect demonstrated a more protective effect, highlighting the importance of 
considering the suite of disseminated and direct effects when dissemination may be 
present. 
 There are several strengths to this approach. As it would be unethical and likely 
unfeasible to conduct a two-stage randomized trial in this population, this ABM-based 
approach provides insights about the direction and magnitude of these various effects. 
Furthermore, we can run numerous simulated trials with different coverage PrEP levels to 
better understand the impact on population-level HIV incidence. To the best of our 
knowledge, this is the first paper to assess causal disseminated effects in the context of an 
ABM and offers additional insight on how to leverage causal inference methodology to 
improve the inference gleaned from simulation-based techniques.  
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This particular agent-based modeling approach has several limitations. We made 
strong assumptions, such as static sexual networks and 100% retention in care during the 
two years of study follow-up. Assuming static components in the sexual networks does not 
accurately reflect the underlying true sexual network; however, if we allow the sexual 
networks to vary over time, there could be a violation of the partial interference or the 
stratified interference assumptions. Future methods work is needed to develop 
appropriate methods for interference structures that change over time. Randomized trials, 
as well as two-stage randomized trials, are subject to Hawthorne effects, and may not 
actually represent the patient experience in medical care. Unfortunately, there are no two-
staged randomized trials of PrEP to compare and contrast our model results; however, 
further comparisons to trial-based estimates of HIV prevalence and incidence could help to 
improve the model to simulate more realistic scenarios that emulate a real-world trial. 
In future work, we will evaluate possible effect modification by component-level 
characteristics, such as HIV prevalence, racial distribution, and substance use prevalence, 
and this information can be used to better allocate resources. We will also extend our 
approach for other study design settings, including cluster-randomized trials and 
observational cohort studies. When the design requires adjustment for confounding at 
either the agent and/or component levels, we will triangulate this approach with a g-
formula approach in the context of dissemination (45, 46). Future work could also compare 
different counterfactual definitions in agent-based models, including simulating potential 
outcomes at the component level. Individuals not on PrEP may benefit by being in a sexual 
network with higher PrEP coverage levels.  
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ABMs are useful to evaluate potential direct and disseminated effects of HIV 
prevention modalities in complex sexual networks among men who have sex with men. 
Employment of these models can provide more timely information about the most 
impactful ways to increase PrEP access, particularly among those underserved in the 
Southern United States.  
 20 
Tables and Figures 
 
Table 1. Cumulative incidence of HIV over two years of follow-up after two-stage randomization among agents within PrEP 
intervention and control components with 95% simulation intervals (SI) in an agent-based model representing among men 
who have sex with men Atlanta, Georgia, 2015-2017 (n = 11,245) 
 
 Agents on PrEP Agents Not on PrEP Control Agents 
Component PrEP 
Coverage Level,% 
Total 
Persons 
HIV+ 
Cumulative 
Incidence 
Total 
Persons 
HIV+ 
Cumulative 
Incidence 
Total 
Persons 
HIV+ 
Cumulative 
Incidence 
10 396.94 17.4 0.044 3098.96 711.5 0.230 4095.03 894.3 0.137 
20 771.12 32.27 0.042 3113.59 612.65 0.197 4091.70 895.05 0.138 
30 1163.53 44.3 0.038 3109.28 519.21 0.167 4100.73 897.47 0.138 
40 1572.93 59.07 0.038 3115.15 432.86 0.139 4096.74 893.14 0.137 
50 1967.04 68.08 0.035 3106.68 339.58 0.109 4093.03 885.55 0.136 
60 2395.52 77.5 0.032 3117.22 257.92 0.083 4083.12 884.76 0.136 
70 2806.26 84.92 0.030 3141.71 183.82 0.059 4065.79 871.33 0.135 
80 3177.9 91.83 0.029 3139.32 120.57 0.038 4037.26 874.74 0.136 
90 3612.07 97.8 0.027 3146.35 50.31 0.013 4031.51 871.25 0.136 
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Table 2. Effects of PrEP on cumulative incidence of HIV over two years of follow-up after 
two-stage randomization among agents within PrEP intervention and control components 
with 95% simulation intervals (SI) in an agent-based model representing men who have 
sex with men, Atlanta, Georgia, 2015-2017 (n = 11,245)1 
 
 
Effect RD 95% SI RR 95% SI 
30% Coverage      
Direct -0.05 -0.06, -0.04 0.18 0.13, 0.24 
Disseminated -0.01 -0.01, 0.00 0.92 0.79, 1.06 
Composite -0.06 -0.06, -0.05 0.17 0.11, 0.22 
Overall -0.02 -0.03, -0.01 0.70 0.60, 0.80 
70% Coverage      
Direct -0.05 -0.06, -0.04 0.17 0.13, 0.23 
Disseminated -0.01 -0.02, 0.00 0.85 0.65, 1.05 
Composite -0.06 -0.06, -0.05 0.15 0.11, 0.20 
Overall -0.04 -0.05, -0.04 0.35 0.28, 0.42 
 
1 RD = Risk Difference; RR = Risk Ratio. 
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Figure 1: Types of causal effects in the context of dissemination (or interference) in two-
stage randomized designs of a pre-exposure prophylaxis (PrEP) intervention in an agent-
based model representing men who have sex with men, Atlanta, Georgia, 2015-2017 (17). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 23 
 
 
Figure 2: Two-stage randomized design to evaluate PrEP for HIV prevention in a population 
of MSM. Trial 1 corresponds to a PrEP allocation strategy with 33% coverage in intervention 
components. Trial 2 corresponds to a PrEP allocation strategy with 66% coverage in 
intervention components. 
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Figure 3. Estimated (a) direct risk difference effects (b) disseminated risk difference effects 
(c) direct risk ratio effects (d) disseminated risk ratio effects of PrEP on cumulative 
incidence of HIV as a function of component PrEP coverage with 95% simulation intervals in 
two-stage randomized designs of a pre-exposure prophylaxis (PrEP) intervention in an 
agent-based model representing men who have sex with men, Atlanta, Georgia, 2015-2017   
 
      
(a)       (b)     
  
   
 
       (c)                                                                                               (d) 
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